850 likes | 1.22k Vues
Immunomodulation in Homotoxicology. Juan Carlos Herrera Correa, MD. Immunological tolerance. Hyporeactivity or non-reactivity of the immune system to an antigen, induced by previous contact with this antigen. IL 10. -TGF. Tolerogenic. Reparative. MALT. MALT. NALT LALT BALT GALT
E N D
Immunomodulation in Homotoxicology Juan Carlos Herrera Correa, MD
Immunological tolerance Hyporeactivity or non-reactivity of the immune system to an antigen, induced by previous contact with this antigen Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
IL 10 • -TGF Tolerogenic Reparative
MALT NALT LALT BALT GALT SALT
Czerkinsky, Cecil; Anjuere, Fabienne; McGhee, Jerry R.; George-Chandy, Annie; Holmgren, Jan; Kieny, Marie-Paule; Fujiyashi, Kohtaro; Mestecky, Jiri F.; Pierrefite-Carle, Valérie; Rask, Carola; Sun, Jia-Bin. Mucosal immunity and tolerance: relevance to vaccine development. Immunological Reviews. Volume 170 August 1999 pp 197-222.
Mucosa-Associated Lymphoid Tissues Brandtzaeg, P. Homing of mucosal immune cells-a possible connection between intestinal and articular inflammation. Alimentary pharmacology & Therapeutics, Supplement. Volume 11 Supplement 3 December 1997 pp 24-39. Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Patients who are allergic to cow’s milk show increased intestinal permeability. • Van Elburg RM, Heymans HS, De Monchy JG. Effect of disodium cromoglycate on intestinal permeability changes and clinical response during cow’s milk challenge. Pediatr Allergy Immunol 1993; 4:79–85. • Schrander JJ, Unsalan-Hooyen RW, Forget PP, et al. [51Cr] EDTA intestinal permeability in children with cow’s milk intolerance. J Pediatr Gastroenterol Nutr 1990; 10:189–92. Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Immunological tolerance and intestinal mucosa • Barrier mechanism: secretion of mucus • Intestinal flora • Mucosal integrity • IgA • MALT regulation mechanisms Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Antigen presentation Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Antigen presentation Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Antigen APC Macrophage CD8 M. Rosales Sdme de Inflamación de las Mucosas. 2nd edition MHC PROCESSEDANTIGEN TCR Th0 IL-10 Th3 Th1 Th2 TGF-B IL-10 IL2, IFN-G, TNF-A IL4, IL5, IL6 IL9, IL10, IL13 Th1 B B Cell-mediated immunity Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006 IGM, IgE, IgG IGA
How does the body react to the entry of an antigen? • Production of antibodies • Anergy or apoptosis • Immunological tolerance Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Normal response in CD 4 + T lymphocytes Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Types of response Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Immunological tolerance Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Schmidt-Weber, C. B.; Blaser, K. T-cell tolerance in allergic response. Allergy: European Journal of Allergy and Clinical Immunology. Volume 57(9) September 2002 pp 762–768 Swiss Institute for Allergy and Asthma Research, Switzerland
Tolerance mechanisms1. Insufficient co-stimulation Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Without co-adjuvants Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Tolerance mechanisms1. Insufficient co-stimulation2. Abundant soluble antigen without adjuvants Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Tolerance mechanisms1. Insufficient co-stimulation2. Abundant soluble antigen without adjuvants3. CTLA4 receptors Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
“Cytolytic T lymphocytes” Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Tolerance mechanisms1. Insufficient co-stimulation2. Abundant soluble antigen without adjuvants3. CTLA4 receptors 4. Slight mutation of antigen structure Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Tolerance mechanisms1. Insufficient co-stimulation2. Abundant soluble antigen without adjuvants3. CTLA4 receptors 4. Slight mutation of antigen structure5. APC-mediated suppression Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
IL 10 Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Tolerance mechanisms1. Insufficient co-stimulation2. Abundant soluble antigen without adjuvants3. CTLA4 receptors 4. Slight mutation of antigen structure5. APC-mediated suppression6. Bystander suppression Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Bystandersuppression Immunological bystander reaction Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Immunological bystander reaction Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Immunological bystander reaction (IBR) Special kind of “low dose antigen reaction” Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
Entry Oral Mucosa-associated lymphoid tissue MALT Other routes Immunological cells of the matrix Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
The potentized proteins of the medicines are immunologically challenged by antigen presenting cells Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
IBR Antigen presenting cells APC Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
IBR Phagocytosis Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
IBR D1-D14 Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
IBR Processing in proteasomes Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
IBR Digestion by lysosomes Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
IBR Short sequences of amino acids (9-15) Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
IBR Coupling to MHC class II Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
IBR Transport via vacuoles Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
IBR To the cell membrane Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
IBR Anchorage in glycocalyx Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
IBR Expression of epitopes Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
IBR Patrolling lymphocytes Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
IBR CD4 T lymphocytes Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006
IBR APC-lymphocyte complex Dr. Juan Carlos Herrera Correa_Immunomodulation_Speakers' Training 2006